We recently showed that B cells reduce CNS inflammation in mice with experimental allergic encephalomyelitis (EAE). Here, we demonstrate that adoptively transferred CD5/CD19+ B cells protect against EAE severity. Furthermore, we show that glatiramer acetate (GA), a therapeutic for relapsing multiple sclerosis treatment, amplifies this effect. Transfer of GA-conditioned B cells leads to increased production of immunoregulatory cytokines and reduced CNS inflammation, as well as decreased expression of the chemokine receptor, CXCR5, and elevated BDNF expression in the CNS. Thus B cells can protect against EAE, and GA augments this effect in maintaining immune homeostasis and controlling EAE disease progression.
Introduction
During the inflammatory process in experimental allergic encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), a T helper 1 (Th1) cell bias is believed to occur in which a variety of cytokines including interferon gamma (IFNγ, interleukin (IL)-12, -23, IL-17, and tumor necrosis factor alpha (TNFα) (Thakker et al., 2007; Begum-Haque et al., 2008) are involved in disease progression, while T helper 2 (Th2) polarization reduces disease activity associated with the secretion of IL-10, IL-4, and transforming growth factor (TGF)-β (Karpus and Swanborg, 1991; Kennedy et al., 1992; Bettelli et al., 1998; Young et al., 2000) . The role of B cells in mediating the inflammatory process is less well understood. B cells are not only central to humoral immunity, but also influence immune and inflammatory responses. They regulate CD4+ T cell responses to foreign and self-antigens (Bouaziz et al., 2007; Xiu et al., 2008) , function as antigen-presenting cells (Constant et al., 1995; Mann et al., 2007) , produce cytokines (Harris et al., 2000; Fillatreau et al., 2002) , provide co-stimulatory signals (Linton et al., 2003) , and promote naïve CD4+ T cell differentiation into Th1 or Th2 subsets (Harris et al., 2000) . B cells also exhibit regulatory activity, as B cell deficient mice develop a severe non-remitting form of EAE (Wolf et al., 1996; Matsushita et al., 2006) . Both Phase I and Phase II clinical trials in MS utilizing a chimeric anti-CD20 monoclonal antibody (rituximab) have implicated B cells as a critical component in MS pathogenesis (Bar-Or, 2008; Hauser et al., 2008) . The effects of the current FDA approved therapies for MS, interferon beta and glatiramer acetate (GA), on the B cell response are not well understood (Gigli et al., 2007; Wiesemann et al., 2008) . Recently published studies suggest that GA can alter B cell responsiveness in MS (Bar-Or et al., 2009) .
Most immunological studies focusing on GA implicate T cells as the primary therapeutic target (Arnon and Sela, 2003; Arnon and Aharoni, 2007) . GA can amplify Th2 polarization associated with the secretion of IL-4, IL-5, and IL-10 (Aharoni et al., 1997). Moreover, GA-sensitized regulatory CD4+ and CD8+ T cells are induced with increased secretion of anti-inflammatory cytokines (Aharoni et al., 1998) . GA can also increase regulatory T cells (Tregs) in EAE mice (Kasper et al., 2007) and enhance differentiation of Tregs in an antigen-independent manner (Weber et al., 2007) . Recently, we reported that GA treatment leads to a reduction in IL-17 expression in the CNS and peripheral tissue of mice with EAE (Begum-Haque et al., 2008) , and also biases towards anti-inflammatory cytokines production by B cells (Begum-Haque et al., 2010) . We describe herein the characteristics associated with B cell regulation in EAE following adoptive transfer of naïve B cells or B cells that had been sensitized with GA. Our findings indicate that transferred B cells can alter EAE disease progression via anti-inflammatory cytokines at the expense of pro-inflammatory cytokines and that GA markedly enhances this effect. Moreover, we 
